Cancer
Egenix Licenses Harvard Anti-Cancer Platform
Published in Cancer Weekly, February 12th, 2008
Mr. Donald Fresne, Chairman and CEO of Egenix, Inc., announced that the company has recently obtained from Harvard University a field-exclusive license under patent rights that cover certain technologies related to cancer therapy and prognostic testing. The licensed technologies, which were developed jointly by scientists in the Laboratory for Translational Research and the Department of Biological Chemistry and Molecular Pharmacology, each of Harvard Medical School, comprise small molecule inhibitors of translation initiation, a new paradigm in target- specific, non-cytotoxic anti-cancer therapy, and the use of translation initiation-specific biomarkers to assess tumor sensitivity to...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-02-12)
More Articles from Cancer Weekly
- Cancer
Lung Cancer, 3rd Edition Available Now - Cancer
Study Finds Widespread Vitamin and Mineral Use Among Cancer Survivors, Although Benefits of Such Use Remain Unclear - Cancer
Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models - Cancer Vaccines
Findings in cancer vaccines reported from R.M. Wong and co-researchers - Cancer Vaccines
New cancer vaccines findings from Shimane University, Medical Department published - Cancer Vaccines
Reports summarize cancer vaccines study results from Charles University - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
